NCT03432429 (REI-EXCISE) is a clinical trial of REIMS iKnife in Breast Cancer, sponsored by Imperial College London.

Who is sponsoring NCT03432429?

NCT03432429 is sponsored by Imperial College London.

What drugs are being tested in NCT03432429?

Interventions in NCT03432429: REIMS iKnife.

What condition does NCT03432429 study?

NCT03432429 studies Breast Cancer, Surgery.

Is NCT03432429 still recruiting?

NCT03432429 is currently completed. Last updated 31 March 2022.

Last reviewed 2022-03-31 · How we verify

NCT03432429: REI-EXCISE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study

Completed Last updated 31 March 2022

What this trial tests

trial testing REIMS iKnife in Breast Cancer in 158 participants. Completed in 8 December 2021.

Timeline

5 September 2017

Primary endpoint
8 December 2021

8 December 2021

Quick facts

Lead sponsor	Imperial College London
Status	Completed
Study type	OBSERVATIONAL
Enrollment	158
Start date	5 September 2017
Primary completion	8 December 2021
Estimated completion	8 December 2021
Sites	3 locations across United Kingdom

Drugs / interventions tested

REIMS iKnife

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Surgery — all drugs for Surgery →

Sponsor

Imperial College London

Who can join

18 and older, female only, with Breast Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

REI-EXCISE is a multicentre, prospective, non-randomised feasibility study, aimed to evaluate the diagnostic accuracy of rapid ionisation mass spectroscopy using an iKnife device. The iKnife will collect vapour, a by-product of surgery, which will pass through the mass spectrometer machine for analysis in order to evaluate what is "normal" and what is "cancerous" breast tissue.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Technologies and techniques to improve precision in breast conserving surgery.
Leff DR. · · 2025 · cited 2× · PMID 39165233 · DOI 10.1002/jso.27657
Biosensors: from personalised medicine to population health.
· 2020 · PMID 32245652 · DOI 10.1016/j.ebiom.2020.102746

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03432429 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 31 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03432429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing